J&J ax­es its big BACE pro­gram in asymp­to­matic Alzheimer's pa­tients as the drum­beat of PhI­II fail­ures rolls on

Re­searchers at J&J $JNJ have pulled the plug on yet an­oth­er BACE pro­gram for Alzheimer’s.

Un­like Mer­ck, which scrapped their lead­ing BACE pro­gram for verube­ce­s­tat …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER